AR046709A1 - Preparacion farmaceutica solida - Google Patents

Preparacion farmaceutica solida

Info

Publication number
AR046709A1
AR046709A1 ARP040104232A ARP040104232A AR046709A1 AR 046709 A1 AR046709 A1 AR 046709A1 AR P040104232 A ARP040104232 A AR P040104232A AR P040104232 A ARP040104232 A AR P040104232A AR 046709 A1 AR046709 A1 AR 046709A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical preparation
solid pharmaceutical
preparation
solid
reabsorption
Prior art date
Application number
ARP040104232A
Other languages
English (en)
Inventor
Ulrich Brauns
Thomas Friedl
Sabine Landerer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10353832A external-priority patent/DE10353832A1/de
Priority claimed from DE102004012045A external-priority patent/DE102004012045A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR046709A1 publication Critical patent/AR046709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparación farmacéutica sólida que contiene uno o más vehículos y/o coadyuvantes sólidos y un principio activo del grupo de los inhibidores de la reabsorción de neurotransmisores monoamínicos, que presentan una estructura de tropano 2, 3- disustituida, su preparación y su uso para la preparación de un medicamento para el tratamiento o la prevención de enfermedades o trastornos del sistema nervioso central.
ARP040104232A 2003-11-18 2004-11-17 Preparacion farmaceutica solida AR046709A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353832A DE10353832A1 (de) 2003-11-18 2003-11-18 Feste pharmazeutische Zubereitungsform
DE102004012045A DE102004012045A1 (de) 2004-03-11 2004-03-11 Feste pharmazeutische Zubereitungsform

Publications (1)

Publication Number Publication Date
AR046709A1 true AR046709A1 (es) 2005-12-21

Family

ID=34621295

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104232A AR046709A1 (es) 2003-11-18 2004-11-17 Preparacion farmaceutica solida

Country Status (18)

Country Link
US (2) US20050124651A1 (es)
EP (1) EP1686965A2 (es)
JP (2) JP2007511559A (es)
KR (1) KR20060125805A (es)
AR (1) AR046709A1 (es)
AU (1) AU2004290520A1 (es)
BR (1) BRPI0416691A (es)
CA (1) CA2545513C (es)
CO (1) CO5690555A2 (es)
HK (1) HK1094676A1 (es)
IL (1) IL175246A0 (es)
MX (1) MXPA06005545A (es)
NO (1) NO20062810L (es)
NZ (1) NZ547880A (es)
PE (1) PE20050479A1 (es)
RU (1) RU2377987C2 (es)
TW (1) TW200529844A (es)
WO (1) WO2005049024A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06005545A (es) * 2003-11-18 2006-08-17 Boehringer Ingelheim Int Preparacion farmaceutica solida.
WO2007028769A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for neuroprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227524A (ja) * 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
JPH07118154A (ja) * 1993-10-22 1995-05-09 Dainippon Pharmaceut Co Ltd 固体分散体および粒状製剤
EE04751B1 (et) * 1996-02-22 2006-12-15 Neurosearch A/S Tropaani derivaadid, nende valmistamine ja kasutamine
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
DK1267880T4 (da) * 2000-02-29 2010-05-17 Bristol Myers Squibb Co Entecavir-formulering med lav dosis og anvendelse deraf
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
US20040106643A1 (en) * 2001-05-23 2004-06-03 Gouliaev Alex Haarh Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DE60216142T2 (de) * 2001-11-30 2007-09-06 Neurosearch A/S Tropan-Derivate mit einer die Wiederaufnahme von Dopamin hemmenden Aktivität zur Behandlung von ischämischen Erkrankungen
US7459464B2 (en) * 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
CA2542442C (en) * 2003-10-16 2012-08-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
MXPA06005545A (es) * 2003-11-18 2006-08-17 Boehringer Ingelheim Int Preparacion farmaceutica solida.
CA2554617A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist

Also Published As

Publication number Publication date
BRPI0416691A (pt) 2007-01-30
AU2004290520A1 (en) 2005-06-02
CA2545513A1 (en) 2005-06-02
WO2005049024A3 (de) 2006-03-30
MXPA06005545A (es) 2006-08-17
EP1686965A2 (de) 2006-08-09
RU2006121446A (ru) 2008-01-10
US20100178342A1 (en) 2010-07-15
RU2377987C2 (ru) 2010-01-10
US20050124651A1 (en) 2005-06-09
JP2007511559A (ja) 2007-05-10
HK1094676A1 (en) 2007-04-04
WO2005049024A2 (de) 2005-06-02
NO20062810L (no) 2006-08-10
KR20060125805A (ko) 2006-12-06
TW200529844A (en) 2005-09-16
NZ547880A (en) 2010-02-26
PE20050479A1 (es) 2005-10-06
CO5690555A2 (es) 2006-10-31
IL175246A0 (en) 2006-10-31
CA2545513C (en) 2013-01-08
JP2011068690A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
AR109590A2 (es) Régimen posológico para inhibidores de comt
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
NO20060871L (no) Azepinderivater som farmasoytiske midler
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
SV2009003403A (es) Extrudidos con enmascaramiento del sabor mejorado
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
PE20011049A1 (es) Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina
NO20070831L (no) Middel for aktivering av tilfriskning fra dysfunksjon etter starten av sentralnevrologisk sykdom.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
AR047726A1 (es) Metodos y reactivos para el tratamiento de trastornos inflamatorios
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
AR046709A1 (es) Preparacion farmaceutica solida
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.

Legal Events

Date Code Title Description
FB Suspension of granting procedure